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Available online 11 June 2016Background: Thyroxine-binding globulin (TBG) is the main transporter of thyroid hormones in human serum,
encoded by the gene TBG (SERPINA7), located in long arm of X-chromosome (Xq21-q22). Deﬁciency of SERPINA7
(serum protease inhibitor, clade A [alpha-1 antiproteinase, antitrypsin], member 7) leads to inherited TBG deﬁ-
ciency. Several mutations have been reported in the coding and noncoding regions of SERPINA7 in association
with TGB deﬁciency.
Methods: Automated chemiluminescence immunoassays were used to determine TSH, free and total T4 and T3
(fT4, TT4, TT3) and TBG. Direct DNA sequencing identiﬁed the mutation in SERPINA7.
Results:We present a 3 and 4/12 year old boy, born premature, whowasmismanaged as hypothyroidism before
referral to our center, and was diagnosed with TBG deﬁciency at our center with a hemizygous substitution in
exon 1, position c.347TNA, leading to replacement of isoleucine for arginine in position 96 (considering the
ﬁrst 20 amino acid signal peptide).
Conclusion: This knownmutation, reported as the ﬁrst SERPINA7mutation in Iran, emphasizes the point that en-
docrinologists should pay more attention to inherited TBG to prevent unnecessary treatment.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Iran1. Introduction
Thyroxine-binding globulin (TBG) is the main transporter of thyroid
hormones in human serum. TBG is encoded by the serum protease in-
hibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7
(SERPINA7), the TBG gene, located on the long arm of the X-
chromosome (Xq21-q22). SERPINA7 loss of function mutations leads
to inherited abnormalities of serum TBG that are either a complete
(TBG-CD), partial (TBG-PD), or excessive (TBG-E). Since SERPINA7 re-
sides on theX chromosome,womenwith homozygous inactivatingmu-
tations and men hemizygous for a deleterious mutation usually
manifest as TBG-CD, and heterozygouswomen as partial [1,2]. Gene du-
plication or triplications have been associated with TBG-E [3].
Inherited defects of TBG do not cause thyroid disease or altered me-
tabolism. Rather, total thyroid hormone (TH) concentrations in serumses Program, National Human
of Health (NIH), Bethesda, MD
yahoo.com (B. Behnam).
, San Juan de Alicante, Spain.
, Ofﬁce of the Clinical Director,
ss article under the CC BY-NC-ND liceare altered while free TH remains unchanged. Medical risks associated
with TBG deﬁciency areminimal if free TH levels aremonitored, but un-
recognized deﬁcienciesmay lead to unsuitable treatment and complica-
tions [4]. Based on published reports, the frequency of TBG deﬁciency
varies from 1 in 1200 to 15,000 newborns; the exact frequency is likely
underestimated due to lack of ability to detect heterozygous females
and males with TBG-PD [5].
TBG is a glycoprotein consisting of 415 amino acids with four N-
linked units of oligosaccharide, synthesized in the liver. The SERPINA7
gene (OMIM +314,200) contains 4 coding exons, spanning ~7.5 kb in
the human genome. Several mutations in the coding and noncoding re-
gions, of SERPINA7 have been reported in associationwith TGB deﬁcien-
cy [5,6]. In this article we present the ﬁrst case report of TBG deﬁciency
in Iran.2. Case presentation
The patient was a 3-year-and-four-month old boy, when seen in the
endocrinology clinic with thyroid dysfunction. At the ﬁrst visit, he could
talk, walk, and run; his height and weight were at the 10%, and he had
near normal intelligence.nse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Primer pairs for SERPINA7.
Primer symbol Primer sequence
SERPINA-1F TGCATCTCCTGTTTTTCAAGG
SERPINA-1R TGTCCAGTGGAGCAGATCAC
SERPINA-2F TGGGAGACCATGACAAATGAC
SERPINA-2R GTTTGTTGATGTGCTTGGATG
SERPINA-3F CCCTACTCCCAGTGCTTCAG
SERPINA-4R TCAGCCAGGGTTCAATCTTC
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of gestation with a weight of 760 g and an Apgar of 5 and 7 at one and
ﬁveminutes. He was resuscitated and received Continuous Positive Air-
way Pressure (CPAP) along with prophylactic surfactant due to respira-
tory distress syndrome (RDS) at birth. He underwent laser therapy for
prematurity retinopathy and was hospitalized for 100 days in NICU
after birth. The proband had a TSH of 2.4 mIU/mL (normal range: 0.2–
8.0 mIU/mL) and a T4 of 2.1 μg/dL (normal range: 6–14.7 μg/dL) at
one month of age, treated with 25 μm of levothyroxine daily. At
22 months, his TSH was 0.3 mIU/L and his T4 was 3.0 μg/dL; the values
reached 1.6 mIU/L and 4.0 μg/dL, respectively, at 24 months of age. At
28 months, the TSH and T4 were 3.1 mIU/L and 2.4 μg/dL, respectively.
A complete blood count (CBC) test in his 30-month age showed a nor-
mal pattern. The measured levels of thyroid hormones are demonstrat-
ed in Table 3. Thyroid hormones were measured by
electrochemiluminescence method with Elecsys 2010 Roche HITACHI
instrument.Fig. 1. Analysis of SERPINA7 exon 1 sequencing. A. Aligned sequence of the patient with p
chromatogram (Chromas software version 2.4.1) for the region containing alterations. Red arrUpon referral to our center, the TSH and T4 levels were 10.1 mIU/L
and 3.0 μg/dL, respectively. After assuring that the patient and family
were compliant, it was concluded that the levothyroxine dosage
(25 mg four days a week) had no effect on serum levels of thyroid hor-
mones; the TSH remained 4.4 mIU/L and the T4 2.9 μg/dL. This
prompted an investigation for genetic disorders. This study was per-
formed in the Molecular Genetics Laboratory of Ali-Asghar Children's
Hospital, Iran University of Medical Sciences, in accordance with the
Declaration of Helsinki. An informed consent was obtained from the
parents on behalf of the child.3. SERPINA7 gene analysis
Genomic DNA was extracted from peripheral blood cells, using a
standard phenol-chloroform protocol. All four coding exons of the
SERPINA7 gene, including intron-exon boundaries, were ampliﬁed by
polymerase chain reaction (PCR) utilizing the primers listed in Table 1.
Single strand sequencing was performed using standard ABI3730 sys-
tem (Applied Biosystems, Macrogen, South Korea) with both forward
and reverse primers. Sequencing results were analyzed using Chromas
version 2.4.1 software, and were aligned to the published template
(ENSG00000123561) using Clustal Omega software (EMBL-EBI). Result
showed a hemizygous substitution in exon 1, position c.347TNA;
p.I116N (p.I96N by numbering from the ﬁrst amino acid of the mature
protein and consider the signal peptide as−1 to−20). The chromato-
gram and aligned sequence are shown in Fig. 1A–B. This change leads to
substitution of a hydrophobic amino acid (isoleucine) to a polar amino
acid (asparagine). After diagnosis of this mutation, treatment for theublished template (ENSG00000123561) in Clustal Omega software. B. Corresponding
ow shows the substituted nucleotide.
Table 2
Reported (non-large deletion) mutations in SERPINA7 gene.
Region Mutation Reference
Exon1 S23T [10]
S23X [11]
D28fsX51 [12]
R35W [32]
R35E [33]
T38fsX51 [13]
P50fs51X [28]
S52N [14]
S52R [31]
S61C [31]
A64D [27]
E74K [31]
I96N [8] & Present study
N112L [31]
A113P [15]
V165fsX168 [16]
D171N [17]
188fsX195 [18]
Exon 2 T191A [19]
D201fsX206 [29]
V215G [34]
Q223X [11]
L227P [20]
N233I [35]
Exon 3 W280X [11,14]
W280fsX325 [9]
L283fsX321 [21]
L283F [20]
Y309P [22]
Exon 4 A329fsX374 [21]
H331Y [23]
K332fsX374 [31]
L352fsX374 [24]
P363L [25,26]
D368G [31]
S370F [36]
Y381fsX396 [4]
R381G [31]
S382R [31]
382fsX384 [21]
L384fsX402 [30]
Non-coding g.IVS1,+2_3insT [5]
H(−2)Y [9]
+20 kb G N A [6]
IVS1 + 2 T N C [30]
15F. Soheilipour et al. / Molecular Genetics and Metabolism Reports 8 (2016) 13–16patient was tapered and he is currently (after two years) not receiving
levothyroxine treatment and is in good condition.4. Discussion
This study reports the ﬁrst case of TBG deﬁciency in Iran with TBG-
CD. Regarding the fact that the patient was born premature, decisionTable 3
The detailed thyroid hormones of the patient in different intervals.
Age Lab item (NL range)
TSH, mIU/ml
(0.2–8.0)
T4, μg/dl
(6–14.7)
T3, ng
(0.75–
1 month 1.5 – –
2 months 2.4 2.1 0.99
4 months 5.8 2.2 0.6
19 months 0.1 5.0 0.9
22 months 0.3 3.0 0.7
24 months 1.6 4.0 –
28 months 3.1 2.4 0.6
30 months (4 weeks after stopping levothyroxine) 10.1 3.0 0.8
36 months (with 1/4 pills levothyroxine) 5.0 3.3 –
40 months 4.4 2.9 1.0on low levels of serum T4 was not enough for initiating the treatment,
as it may be due to physiologic hypothyroxinemia of prematurity [7].
For premature infantswith puzzling thyroid hormone tests, FT4 is a bet-
ter evaluation that should have been considered for the present patient
to avoid unnecessary treatment for more than two years, which might
unnecessarily predispose the infant to the adverse effects of the drug.
When the patient was ﬁrst visited by our team, molecular genetic anal-
ysis revealed a hemizygous substitution, c.347TNA; p.I116N (p.I96N in
mature protein); thus, levothyroxine was tapered and discharged.
Isoleucine 96 resides in a highly conserved domain of the protein
that is preserved among human, chimpanzee, mouse, rat, pig, bovine
and sheep, and is a site of glycosylation. This variant, which is known
as TBG-Gary, has been previously reported (http://www.ncbi.nlm.nih.
gov/clinvar/variation/9790/) and associatedwith severe TBGdeﬁciency.
This alteration damages a potential glycosylation domain by creating a
new site (Asn-Cys-Ser), therefore results in encoding a proteinwith im-
paired T4 binding ability and severe instability that causes rapid dena-
turation [8]. This mutation is known to cause TBG-PD, however in our
hemizygote case, it leads to complete deﬁciency (TBG-CD).
In TBG-CD serum concentration for TBG is usually below 5 mg/L,
while in TBG-PD it overlaps the normal concentration in heterozygote
females. To date, about 45 mutations have been described to cause
TGB deﬁciency, mostly in coding regions [5–6,8–36] (Table 2) (recently
reviewed by Pappa et al. [31]). There does not appear to be a “hot spot”;
missense and nonsense mutations are scattered in coding regions and
splice sites. Themajority of alterations that lead to TBG-CD are nonsense
mutations that drastically change the amino acid sequence and conse-
quently the proper function of protein [5]. Some reports also described
mutations in non-coding regions, whichmostly affectmRNA splicing [9,
18]. Recently, in four families that showed no mutations in SERPINA7,
Ferrara and colleagues discovered a new variant 20 kb downstream of
the gene. This alteration resideswithin a liver-speciﬁc enhancer, leading
to reduction in the activity and consequently the expression of the
SERPINA7 [6].Conﬂict of interest
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2.0)
fT4, pmol/l
(10.29–36.03)
T3RU, %
(25–35%)
FTI
(1.12–4.37)
T3RIA, ng/dL
(80–200)
T4RIA, μg/dL
(4.5–12.5)
12.87 – – 40 1.9
25.74 31 – 70 3.3
– 35 – – –
41.0 – – – –
23.4 37.7 1.13 – –
30.2 40.1 1.70 – –
– – – – –
4.3 36.5 1.10 – –
10.1 36.5 1.20 – –
14.157 33 – – –
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